Lifetime end‐stage kidney disease risk estimation in living kidney donor candidates remains a challenge

Publisher： John Wiley & Sons Inc

E-ISSN： 1432-2277|31|1|118-120

ISSN： 0934-0874

Source： TRANSPLANT INTERNATIONAL (ELECTRONIC), Vol.31, Iss.1, 2018-01, pp. : 118-120

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Cochrane commentary

By  

NEPHROLOGY, Vol. 20, Iss. 4, 2015-04 ,pp. : 302-303

John Wiley & Sons Inc

Access to resources Recommend Favorite

Anticancer Drugs in End‐Stage Kidney Disease Patients

By  

SEMINARS IN DIALYSIS, Vol. 28, Iss. 4, 2015-07 ,pp. : 413-416

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clopidogrel Use in End‐Stage Kidney Disease

By  

SEMINARS IN DIALYSIS, Vol. 28, Iss. 3, 2015-05 ,pp. : 276-281

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prevalence of Chronic Kidney Disease and Associated Risk Factors, and Risk of End-Stage Renal Disease: Data from the PREVADIAB Study

By  

Nephron Clin Pract, Vol. 119, Iss. 1, 2011-06 ,pp. : c35-c40

Karger

Access to resources Recommend Favorite

The Risk of End‐Stage Renal Disease Among Living Donor Liver Transplant Recipients in the United States

By  

AMERICAN JOURNAL OF TRANSPLANTATION, Vol. 1600-6135, Iss. 10, 2015-10 ,pp. : 2732-2738

John Wiley & Sons Inc

Access to resources Recommend Favorite